Vanda Pharmaceuticals (VNDA) Other Accumulated Expenses (2011 - 2018)

Vanda Pharmaceuticals has reported Other Accumulated Expenses for 8 years, with the latest figure at $4.4 million in Q1 2018.

• Quarterly Other Accumulated Expenses rose 134.23% year-over-year to $4.4 million in Q1 2018, while the trailing twelve-month figure through Mar 2018 was $4.4 million (up 134.23% YoY) and the FY2017 annual result came in at $4.4 million, down 3.53% from the prior year.
• Other Accumulated Expenses declined to $4.4 million in Q1 2018 per VNDA's latest filing, from $4.4 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $6.4 million in Q3 2016 and troughed at $614000.0 in Q1 2014.
• A 5-year average of $2.9 million and a median of $2.0 million in 2014 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2014 and 2017: Other Accumulated Expenses soared 4555.56% in 2014, then plunged 69.76% in 2017.
• Over 5 years, Other Accumulated Expenses stood at $2.0 million in 2014, then soared by 163.76% to $5.3 million in 2015, then fell by 14.51% to $4.6 million in 2016, then slipped by 3.53% to $4.4 million in 2017, then decreased by 0.96% to $4.4 million in 2018.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $4.4 million, $4.4 million, and $1.9 million for Q1 2018, Q4 2017, and Q3 2017 respectively.